- Home
- WLYB vs HCM Comparison
WLYB vs HCM Comparison
Compare WLYB & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- HCM
- Stock Information
- Founded
- WLYB 1807
- HCM 2000
- Country
- WLYB United States
- HCM Hong Kong
- Employees
- WLYB N/A
- HCM N/A
- Industry
- WLYB Books
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- HCM Health Care
- Exchange
- WLYB Nasdaq
- HCM Nasdaq
- Market Cap
- WLYB 2.4B
- HCM 2.6B
- IPO Year
- WLYB N/A
- HCM N/A
- Fundamental
- Price
- WLYB $43.70
- HCM $14.20
- Analyst Decision
- WLYB
- HCM Hold
- Analyst Count
- WLYB 0
- HCM 1
- Target Price
- WLYB N/A
- HCM $19.00
- AVG Volume (30 Days)
- WLYB 255.0
- HCM 77.7K
- Earning Date
- WLYB 03-06-2025
- HCM 02-26-2025
- Dividend Yield
- WLYB 3.22%
- HCM N/A
- EPS Growth
- WLYB N/A
- HCM N/A
- EPS
- WLYB N/A
- HCM N/A
- Revenue
- WLYB $1,759,570,000.00
- HCM $610,806,000.00
- Revenue This Year
- WLYB N/A
- HCM N/A
- Revenue Next Year
- WLYB $1.13
- HCM $20.69
- P/E Ratio
- WLYB N/A
- HCM N/A
- Revenue Growth
- WLYB N/A
- HCM N/A
- 52 Week Low
- WLYB $32.60
- HCM $11.93
- 52 Week High
- WLYB $52.90
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- WLYB 43.40
- HCM 42.32
- Support Level
- WLYB $41.61
- HCM $13.00
- Resistance Level
- WLYB $52.29
- HCM $15.29
- Average True Range (ATR)
- WLYB 0.10
- HCM 0.46
- MACD
- WLYB 0.28
- HCM -0.00
- Stochastic Oscillator
- WLYB 85.31
- HCM 37.74
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is a provider of academic journals, books, pre- and post-hire assessments and training, test preparation materials, and online education program management solutions. The company's reportable segments are; Research, Learning, Held for Sale or Sold. The majority of the company's revenue is generated from the Research segment which provides peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. Geographically, it derives maximum revenue from the United States and the rest from the United Kingdom, China, Japan, Canada, and other countries.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.